Daurismo (glasdegib) prior authorization and coverage criteria
Prior authorization and coverage criteria for Daurismo (glasdegib) for treatment of newly-diagnosed acute myeloid leukemia (AML), including initial and reauthorization rules and pediatric automatic processing. Affects providers prescribing glasdegib under the payer program.
Removed relapsed/refractory disease as a component of repeating the initial successful induction regimen per uses no longer recommended by NCCN.
Added general NCCN recommendations for use criteria and examples of significant comorbidities that preclude intensive induction chemotherapy.
Updated references (package insert and NCCN Compendium) through December 2024/2025.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.